Clinical trials: Prostate Disease
Prostate Cancer
Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
Primary Objective: To assess the tolerability of cabazitaxel 25 mg per body surface area (m^2) with primary prophylactic polyethylene glycol-granulocyte-colony stimulating factor (PEG-G-CSF) in terms of the incidence rate of…
- Trial name
- PEGAZUS (NCT02441894)
- Testing
- CABAZITAXEL XRP6258, PEG-G-CSF, Prednisolone
- Where
- 8 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Sanofi
Prostate Cancer
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH).
- Trial name
- NCT00444639
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 15 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Ipsen
Cancer, Carcinoma
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity…
- Conditions
- Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00838201
- Testing
- Denosumab
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 384 people
- Sponsor
- Amgen
BPH, Benign Prostatic Hyperplasia
An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice.
- Trial name
- NCT05422677
- Testing
- Hanmi Tams® Capsule
- Where
- South Korea
- Volunteers
- 4,698 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Prostate Cancer
PK and Dose Escalation and Expansion Study of DST-2970
This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation…
- Trial name
- NCT04291664
- Testing
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- DisperSol Technologies, LLC
Benign Prostatic Hyperplasia
A Study to Assess the Effect of Fucoidan on Prostate Health in Males With Benign Prostatic Hyperplasia
The present study is a randomized, double-blind, placebo-controlled study. Approximately 125 individuals will be screened, and considering a screening failure rate of 20%, at least 100 will be randomized in a ratio of 1:1 to…
- Trial name
- NCT06487871
- Testing
- Fucoidan extracted from Undaria pinnatifida (UPF)
- Where
- 6 sites in India
- Volunteers
- 95 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 5 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Metastatic Castration Resistant Prostate Cancer
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
- Trial name
- NCT06517719
- Testing
- lutetium (177Lu) vipivotide tetraxetan
- Where
- 38 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Bone Metastases
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
- Trial name
- NCT00757757
- Testing
- MCS110
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Benign Prostatic Hyperplasia
Temperature Mapping of the Prostate With the Wallterm™ System
To measure intra-prostatic temperatures and evaluate the shape and size of necrotic lesions achieved under the standard treatment protocol in men with benign prostatic hyperplasia (BPH).
- Trial name
- WT-DK-TMW08 (NCT00662350)
- Testing
- The Wallterm™ System
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Pnn Medical A/S
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Prostate Cancer
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
- Trial name
- TITAN (NCT02489318)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 220 sites in United States, Argentina and 20 more
- Volunteers
- 1,052 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVIDE Studies Post Exit Analysis
A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.
- Trial name
- NCT07680543
- Testing
- ProVee Urethral Expander System
- Volunteers
- 25 people
- Sponsor
- ProVerum Medical
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Benign Prostatic Hyperplasia
A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia
This is a prospective, multicentre, non-interventional study, conducted in France and Spain, in primary care practices and designed to assess the QoL of patients under phytotherapy or alpha-blockers for LUTS/BPH.
- Trial name
- PERQoL (NCT07144709)
- Testing
- Phytotherapy
- Where
- 31 sites in France, Spain
- Volunteers
- 288 people
- Sponsor
- Pierre Fabre Medicament
Prostate Cancer, Psychosocial Stressor
Feasibility of Technology-Based SSIP in Prostate Cancer Patients
The goal of this pilot study is to assess the perceived usability of a smartphone application called WINGS targeting psychosocial distress and well-being in prostate cancer patients and their social network.
- Trial name
- NCT05720832
- Testing
- WINGS-IP1 Smartphone Application
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Wings Health AG
Neoplasms, Prostate
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
- Trial name
- NCT00363311
- Testing
- Dutasteride
- Where
- 82 sites in United States, Canada
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.
- Trial name
- MCS-2-US-c (NCT01002222)
- Testing
- MCS-2
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.